Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
REGENERON PHARMACEUTICALS, INC. (CIK 872589) reported $177.2M across 3 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PBLS ($114.0M, 64.35%), NTLA ($62.7M, 35.35%), ACET ($522,819, 0.30%), ACET ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PBLS | Parabilis Medicines, Inc. | $114.0M | 64.35% | 4.2M | New |
| 2 | NTLA | Intellia Therapeutics, Inc. | $62.7M | 35.35% | 3.7M | Hold |
| 3 | ACET | Adicet Bio, Inc. | $522,819 | 0.30% | 60,511 | New |
| 4 | ACET | Adicet Bio, Inc. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30